Cargando…

Origin and mechanism of neuroblastoma

Detalles Bibliográficos
Autores principales:	Tsubota, Shoma, Kadomatsu, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616197/ https://www.ncbi.nlm.nih.gov/pubmed/28966937 http://dx.doi.org/10.18632/oncoscience.360

Ejemplares similares

Neuroblastoma stem cells and CFC1
por: Tsubota, Shoma, et al.
Publicado: (2017)

A New Tumorsphere Culture Condition Restores Potentials of Self-Renewal and Metastasis of Primary Neuroblastoma in a Mouse Neuroblastoma Model
por: Cao, Dongliang, et al.
Publicado: (2014)

Combination of tumor necrosis factor‐α and epidermal growth factor induces the adrenergic‐to‐mesenchymal transdifferentiation in SH‐SY5Y neuroblastoma cells
por: Huang, Yue, et al.
Publicado: (2020)

Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN‐amplified neuroblastoma cells
por: Yamashita, Ken, et al.
Publicado: (2020)

NeuroD1 promotes neuroblastoma cell growth by inducing the expression of ALK
por: Lu, Fangjin, et al.
Publicado: (2015)

Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes
por: Su, Zhendong, et al.
Publicado: (2017)

Screening of novel Midkine binding protein by BioID2-based proximity labeling
por: Komata, Yosuke, et al.
Publicado: (2021)

Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation
por: Nakaguro, Masato, et al.
Publicado: (2015)

Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma
por: Ho, Wan-Ling, et al.
Publicado: (2016)

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
por: Zhai, Lei, et al.
Publicado: (2023)

Heterogeneity of neuroblastoma
por: Ngan, Elly Sau-Wai
Publicado: (2015)

Neuroblastoma by chance
por: Tonini, Gian Paolo
Publicado: (2019)

Neuroblastoma cancer in children
por: Nagaich, Upendra
Publicado: (2019)

Molecular Determinants of Neuroblastoma
por: Morandi, Fabio
Publicado: (2022)

Fighting Neuroblastomas with NBAT1
por: Pandey, Gaurav Kumar, et al.
Publicado: (2015)

CYLD and SUMO in neuroblastoma therapy
por: Masoumi, Katarzyna Chmielarska, et al.
Publicado: (2016)

The role of ICAM-2 in neuroblastoma
por: Yoon, Karina J., et al.
Publicado: (2015)

Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019)

Surgical Advances in Paediatric Neuroblastoma
por: Martucciello, Giuseppe
Publicado: (2022)

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018)

Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas
por: Ikematsu, S, et al.
Publicado: (2003)

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
por: Hasan, Md. Kamrul, et al.
Publicado: (2013)

Recent advances in the developmental origin of neuroblastoma: an overview
por: Ponzoni, Mirco, et al.
Publicado: (2022)

Spy1/SpeedyA accelerates neuroblastoma
por: Bisteau, Xavier, et al.
Publicado: (2014)

Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2014)

Spy'ing on differentiation in neuroblastoma
por: Podkowa, Monika, et al.
Publicado: (2014)

High-SETD8 inactivates p53 in neuroblastoma
por: Veschi, Veronica, et al.
Publicado: (2017)

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016)

Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2006)

GDE2/GDPD5 in neuroblastoma
por: Matas-Rico, Elisa, et al.
Publicado: (2016)

Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
por: Matthay, K K, et al.
Publicado: (2000)

Neuroblastoma Mass Screening—What Can We Learn From It?
por: Katanoda, Kota
Publicado: (2016)

Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis
por: Kitai, Hiroki, et al.
Publicado: (2022)

Correction: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2007)

Screening for Neuroblastoma Using Urinary Catecholamines: The End of the Story
por: Woods, William G
Publicado: (2021)

Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity
por: Yang, Chia-Lung, et al.
Publicado: (2020)

The Keio Medical Science Prize for 2015
por: Tsubota, Kazuo
Publicado: (2016)

The first human clinical study for NMN has started in Japan
por: Tsubota, Kazuo
Publicado: (2016)

Aging science comes of age
por: Tsubota, Kazuo
Publicado: (2015)

Real frontier in clinical applications of regenerative medicine
por: Tsubota, Kazuo
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bpv8834nd151gsn9l9ss8qhq56